Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 2/20 | 0.36 |
| ▸ | HSPA5 | P11021 | 2/20 | 0.34 |
| ▸ | HSPA8 | P11142 | 2/20 | 0.34 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2584815 | 0.90 | HSPA5 (0.37) | ADKHSPA5HSPA8RNASELRXFP1 | |
| SCHEMBL2587219 | 0.87 | HSPA8 (0.34) | ADKHSPA5HSPA8RXFP1SLC28A2 | |
| SCHEMBL2584063 | 0.85 | SMN1; SMN2 (0.38) | SLC28A2HPGDLMNATP53 | |
| SCHEMBL2579338 | 0.82 | HSPA8 (0.35) | ADKHSPA5HSPA8RNASELRXFP1 | |
| SCHEMBL2578106 | 0.82 | ADK (0.50) | ADKHSPA5HSPA8RXFP1SLC28A2 | |
| SCHEMBL2587610 | 0.78 | SLC28A2 (0.35) | HSPA5HSPA8RXFP1SLC28A2 | |
| SCHEMBL2584222 | 0.77 | ADORA1 (0.37) | SLC28A2 | |
| SCHEMBL2579342 | 0.76 | SMN1; SMN2 (0.38) | SLC28A2TP53 | |
| SCHEMBL6886934 | 0.73 | SLC29A1 (0.51) | SLC28A2LMNATP53 | |
| SCHEMBL2589332 | 0.71 | HSPA8 (0.52) | ADKHSPA5HSPA8RXFP1SLC28A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10100076-B2 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | GILEAD PHARMASSET LLC (US) | 2018-10-16 | — | — | US | disclosed |
| US-20140057863-A1 | MODIFIED NUCLEOSIDES FOR THE TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | GILEAD SCIENCES, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| EP-2251015-B1 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | GILEAD PHARMASSET LLC (US) | 2013-02-20 | — | — | EP | disclosed |
| US-20110269707-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellullar proliferation | PHARMASSET, INC. | 2011-11-03 | — | — | US | disclosed |
| EP-2251015-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | Pharmasset, Inc. (US) | 2010-11-17 | — | — | EP | disclosed |
| US-20030087873-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | PHARMASSET, INC. | 2003-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140057863-A1 | MODIFIED NUCLEOSIDES FOR THE TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | SLC29A1, PNP, SLC29A2 | ADK 1008/4885HSPA5 1617/4885HSPA8 4823/4885 |
| US-20110269707-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellullar proliferation | PNP, ALPP, XDH | ADK 876/4885HSPA5 2063/4885HSPA8 4599/4885 |
| US-10100076-B2 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | SLC29A1, SLC29A2, PNP | ADK 1033/4885HSPA5 2286/4885HSPA8 4839/4885 |
| US-20030087873-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | SLC29A1, PNP, SLC29A2 | ADK 1127/4885HSPA5 1835/4885HSPA8 4815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.